Previous Section Index Home Page

17 Mar 2009 : Column 1022W—continued


Annual prevalence (of consultation) per 10,000 by age and gender

Age s tandardised (95 per cent. CI) All ages < 1 1 -4 5-14 15-24 25-44 45-64 65-74 75+

Asthma (493)

M

412 (403-422)

409

41

440

690

441

353

323

429

396

F

482 (472-493)

484

16

282

501

609

472

488

546

411

Source:
RCGP Weekly Returns Service.

Bone Marrow Disorders

Mike Penning: To ask the Secretary of State for Health how many people are on the waiting list for bone marrow transplants in (a) Hemel Hempstead and (b) Hertfordshire. [263732]

Ann Keen: The Department does not hold this information centrally.

Cancer: Drugs

Dr. Gibson: To ask the Secretary of State for Health for what reasons his Department recommended that temsirolimus should be referred to the National Institute for Health and Clinical Excellence for appraisal as part of the multiple technology appraisal in the treatment of renal cell carcinoma. [263474]


17 Mar 2009 : Column 1023W

Ann Keen: Temsirolimus was referred to the National Institute for Health and Clinical Excellence (NICE) as part of the multiple technology appraisal of drugs for the treatment of renal cell carcinoma in September 2007, following a consultation by NICE with stakeholders on the proposed remit and scope for the appraisal. Information on this consultation, including a summary of responses, is available on the NICE website at:

Childbirth

Anne Milton: To ask the Secretary of State for Health pursuant to the answer from the Chancellor of the Duchy of Lancaster on 24 February 2009, Official Report, column 634W, on childbirth, what use his Department has made of the figures on survival to age one of babies born in England and Wales by gestation weeks produced by the Office for National Statistics in its research into (a) premature babies and (b) neonatal deaths. [263578]

Ann Keen: The Department funds but does not directly undertake research concerned with premature birth and neonatal death. We expect the researchers we support to be aware and make appropriate use of vital statistics such as those published by the Office for National Statistics.

Chlamydia: Screening

Anne Milton: To ask the Secretary of State for Health what estimate he has made of the number of Chlamydia tests carried out in (a) genito-urinary medicine clinics, (b) GP surgeries and (c) pharmacies in each of the last five years. [263576]

Ann Keen: Data on the number of sexual health screens, which includes a test for Chlamydia, in genitourinary medicine (GUM) clinics between 2003 and 2007, the latest year for which figures are available, are shown in the following table.

Sexual health screens

Number

2003

633,289

2004

727,010

2005

810,140

2006

883,488

2007

1,022,801

Notes:
1. One sexual health screen includes a test for Chlamydia and gonorrhoea at minimum and this is considered as one screen.
2. The data available from the KC60 statutory returns are for Chlamydia tests in GUM clinics only. Chlamydia tests in other clinical settings, such as general practice, are not recorded in the KC60 dataset.
3. The data available from the KC60 statutory returns are the number of tests made, not the number of patients tested.
4. The information provided has been adjusted for missing clinic data.
5. Data are unavailable for 2008
Source:
Health Protection Agency, KC60 returns

In addition to sexual health screens in GUM clinics, the National Chlamydia Screening Programme (NCSP) provides screening for Chlamydia to asymptomatic people aged under 25 years of age in healthcare and non- healthcare settings across England. The NCSP was launched in 2003. The following table shows the total number of Chlamydia tests done in general practice and pharmacies among 15-24 year-olds during the period 1 April 2003-31March 2008.


17 Mar 2009 : Column 1024W
Venue type

General practitioner surgeries Pharmacies

2003-04

2,445

0

2004-05

7,426

36

2005-06

17,281

8,272

2006-07

23,271

13,309

2007-08

43,046

9,052

Notes:
1. Data includes Chlamydia tests for males, females, and those with unknown/unspecified sex.
2. Data presented are the number of Chlamydia tests performed and not number of people tested. It should be noted that the number of Chlamydia tests collected through the NCSP will be used as a proxy for the number of people tested.
3. Data presented are based on tests with confirmed positive and negative results only. Tests with equivocal, inhibitory and insufficient results have been excluded as most people with these results are retested.
4. Data presented are based on young people resident in England only.
5. The total number of tests will increase annually as the NCSP was rolled out in phases across England with participation of all 152 primary care trusts occurring at the end of 2007-08.
6. The total number of tests done in pharmacies increased substantially in 2005-06 because the Boots Pathfinder pilot was run between November 2005 and March 2008. The pilot project was based on Chlamydia testing being made available in selected Boots pharmacies across London.
Source:
National Chlamydia Screening Programme

Clostridium

Mr. Lansley: To ask the Secretary of State for Health with reference to the answer of 10 September 2008, Official Report, columns 1882-3W, on clostridium, how often cancer was mentioned on the death certificates on which (a) MRSA and (b) clostridium difficile was mentioned in each year. [263677]

Ann Keen: The information is shown in the following tables. Figures for Methicillin-resistant Staphylococcus aureus (MRSA) are for the year 1997 to 2007, and for Clostridium difficile for the years 1999 and 2001 to 2007, the latest year for which figures are available.

Deaths involving Clostridium difficile( 1,2) where cancer( 3) was also mentioned on the death certificate, England and Wales( 4) , 1999, 2001 to 2007( 5)
Persons

Deaths

1999

74

2001

94

2002

132

2003

160

2004

236

2005

394

2006

796

2007

1,168

(1) Identified using the methodology described in Office for National Statistics (ONS): Report: Deaths involving Clostridium difficile: England and Wales, 2001-2005. Health Statistics Quarterly 33, 71-75.
(2) Deaths involving Clostridium difficile can only be identified using the Tenth Revision of the International Classification of Diseases (ICD-10). This has been used by ONS for coding mortality from 2001 onwards and in 1999 for a bridge coding study. Data are therefore not available for 2000 when the Ninth Revision of the ICD was in use.
(3) Cause of death for cancer was defined using the International Classification of Diseases, Tenth Revision (ICD-10) codes C00-C97.
(4) Figures for England and Wales include deaths of non-residents.
(5) Figures are for deaths registered in each calendar year.


17 Mar 2009 : Column 1025W
Deaths involving Methicillin -resistant Staphylococcus aureus( 1) where cancer( 2) was also mentioned on the death certificate, England and Wales( 3) , 1999 to 2007( 4)
Persons

Deaths

1997

115

1998

118

1999

102

2000

170

2001

124

2002

149

2003

181

2004

218

2005

305

2006

283

2007

271

(1) Identified using the methodology described in Griffiths C, Lamagni TL, Crowcroft NS, Duckworth G and Rooney C (2004). Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993-2002. Health Statistics Quarterly 21, 15-22.
(2) Cause of death for cancer was defined using the International Classification of Diseases, Ninth Revision (ICD-9) codes 140-208 for 1999 to 2000 and Tenth Revision (ICD-10) codes C00-C97 for 2001 to 2007. The introduction of ICD-10 in 2001 means that the number of deaths from this cause, before 2001 are not completely comparable with later years.
(3) Figures for England and Wales include deaths of non-residents.
(4) Figures are for deaths registered in each calendar year.

17 Mar 2009 : Column 1026W

Mr. Lansley: To ask the Secretary of State for Health with reference to the answer of 10 September 2008, Official Report, columns 1882-83W, on clostridium, which five other conditions were mentioned most frequently on the death certificates on which (a) MRSA and (b) clostridium difficile was mentioned in each year; and how often each such condition was mentioned in each year. [263678]

Ann Keen: The information requested is shown in the following tables. Figures for Methicillin-resistant Staphylococcus aureus (MRSA) are available for the years 2001 to 2007, and for Clostridium difficile for the years 1999 and 2001 to 2007, the latest year for which figures are available.

Table 1: The five causes of death( 1) mentioned most frequently on death certificates on which MRSA( 2) was also mentioned, England and Wales( 3) ,2001-07( 4,5)
Deaths (persons)
Causes of death 2001 2002 2003 2004 2005 2006 2007 ICD codes

Cerebrovascular diseases

*

140

*

174

265

*

*

I60-I69

Diabetes

148

*

*

*

*

*

253

E10-E14

Diseases of the musculoskeletal system and connective tissue

147

143

178

187

274

284

250

M00-M99

Diseases of the urinary system

260

300

363

393

505

535

498

N00-N39

Heart failure and complications and ill-defined heart disease

*

*

175

*

*

264

*

I50-I51

Influenza and pneumonia

206

192

246

264

401

401

453

J10-J18

Ischaemic heart diseases

196

221

267

311

396

442

404

I20-I25

(1) Selected using International Classification of Diseases, Tenth Revision (ICD-10) code groups published in: Griffiths C, Rooney C and Brock A (2005) Leading causes of death in England and Wales—how should we group causes? “Health Statistics Quarterly” 28, p6-17. Codes used to identify MRSA deaths were excluded.
(2) Identified using the methodology described in Griffiths C, Lamagni TL, Crowcroft NS, Duckworth G and Rooney C (2004). Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993-2002. “Health Statistics Quarterly” 21, 15-22.
(3 )Figures for England and Wales includes deaths of non-residents.
(4) Data are for deaths registered in each calendar year.
(5) An asterisk (*) denotes this was not one of the five causes of death mentioned most frequently in this year.

Next Section Index Home Page